Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 14 November, 2000

XTL Biopharm Ltd

Re Alliance

XTL Biopharmaceuticals Limited
14 November 2000

XTL Biopharmaceuticals Ltd.               Pharming Group N.V.

Kiryat Weizmann                           P.O. Box 451

P.O. Box 370, Rehovot 76100, Israel       2300 AL Leiden, The Netherlands

Tel: 972 8 9405 134                       Tel: +31 71 524 74 00

Fax: 972 8 9405 017                       Fax: +31 71 521 65 07                  

For Immediate Release

                                 HEPATITIS C

   -Agreement between XTL and Pharming Designed to Evaluate and Potentially
        Co-Develop Biopharmaceutical Protein for Use in Treating HCV-

Leiden, The Netherlands, Rehovot, Israel and New Ipswich, NH, November 14,
2000 - XTL Biopharmaceuticals Ltd. ('XTL') (LSE: XTL) and Pharming Group N.V.
('Pharming') (EASDAQ: PHAR and AEX: PHAR) today announced the signing of an
agreement to jointly evaluate and potentially co-develop recombinant human
Lactoferrin (rhLF) as a treatment for hepatitis C virus (HCV). Human
Lactoferrin is a natural protein with antibiotic, probiotic, anti-inflammatory
and immuno-modulating properties. Financial terms of the deal were not

'This agreement with Pharming represents XTL's most advanced stage partnership
to date and will provide depth to our increasing portfolio of potential
therapeutics to treat HCV,' stated Glenn Kazo, General Manager and Business
Officer of XTL Biopharmaceuticals Inc., based in the United States. 'We are
confident that this collaboration with Pharming, combined with XTL's
technology, will provide synergy to further develop our product pipeline.'

Pharming's President and CEO George J. M. Hersbach commented that: 'The
co-development agreement with XTL offers us the opportunity to combine our
technology with that of XTL's to evaluate and pursue the use of Pharming's
rhLF as a treatment for Hepatitis C, a serious chronic disease that affects a
rapidly increasing number of people worldwide.'

The development of Pharming's recombinant human Lactoferrin (rhLF) as a
potential treatment for infectious diseases is on track. Pharming successfully
completed a phase I clinical trial of intravenously administered rhLF that
demonstrated rhLF was well tolerated up to the highest dose of 60 mg/kg. This
excellent safety profile, combined with promising data from pre-clinical
studies, suggest that rhLF is a realistic therapeutic candidate for infectious
diseases, including HCV.

HCV is a major cause of chronic hepatitis in the United States and is a
leading cause for liver transplantation. The World Health Organization
estimates that 170 million people are infected with HCV worldwide,
approximately four million of whom are in the United States. Eighty five
percent of HCV infected persons will develop chronic hepatitis, of which 10-20
percent will progress to liver cirrhosis. The number of deaths attributable to
hepatitis C is expected to increase substantially in the next 10 to 20 years.

XTL Contacts:                                    Pharming Contacts:

Martin Becker, PhD, President and CEO            Rob Meines

Tel: +972 8 940 5134                             Praaning Meines Consultancy
Glenn Kazo, General Manager & Chief Business
Officer                                          Tel: +31 71 5247 429

Tel: +1 603 878 9857                             Tonua Fedusenko

David Yates / Sarah Mehanna                      KF Dunn & Associates

Financial Dynamics                               Tel: +1 302 328 3347

Tel: +44 (0) 20 7831 3113

Notes to Editors

Pharming Group

Pharming focuses on the development, production and commercialization of human
therapeutic proteins to be used in highly innovative therapies. Pharming has
developed a proprietary production platform of transgenic animals, capable of
producing human therapeutic proteins at high levels in their milk. Pharming's
product portfolio is aimed at treatments for genetic disorders, surgery and
trauma, infectious and inflammatory diseases, tissue and bone repair and
blood-related disorders. Pharming has operations in Belgium, Finland, the
Netherlands and the USA and currently employs more than 200 people.

XTL Biopharmaceuticals

XTL is developing therapeutics to treat hepatitis B, hepatitis C and other
infectious diseases using human monoclonal antibodies and synthetic chemical
products. XTL's competitive advantage lies in its proprietary Trimera
technology, which enables XTL to accelerate its internal product development
and to secure rights to drug candidates and other technology from third
parties. For more information about XTL, visit XTL's website at

For Pharming: The statements that are not historical facts contained in this
release are forward-looking statements and are made pursuant to the safe
harbor provisions of the Securities Litigation Reform Act of 1995. Such
statements involve risks and uncertainties that may differ materially from
those set forth in these statements. In addition, the economic, competitive,
governmental, technological and other factors identified in AVI's filings with
the Securities and Exchange Commission could affect such results.

                                    £ £ £